Clinical trials for triple-negative breast cancer (TNBC) are an exciting area of research, with companies, research institutions, and nonprofits all working together to find better treatments. They can be a great option, especially if standard treatments haven't worked as well as hoped. Some of the treatment approaches Show Full Answer
Clinical trials for triple-negative breast cancer (TNBC) are an exciting area of research, with companies, research institutions, and nonprofits all working together to find better treatments. They can be a great option, especially if standard treatments haven't worked as well as hoped. Some of the treatment approaches currently being explored in clinical trials include:
- Immunotherapy combinations – such as pairing checkpoint inhibitors with chemotherapy
- PARP inhibitors – like olaparib and talazoparib, especially for those with BRCA gene mutations
- Antibody-drug conjugates – targeted medicines that deliver chemotherapy directly into cancer cells
- Chemoimmunotherapy – combining chemotherapy with immunotherapy drugs like pembrolizumab
These trials aim to improve outcomes for people whose cancer continues to grow despite existing treatments. To find trials you may be eligible for, a great starting point is talking to your oncologist. You can also search for open studies at ClinicalTrials.gov or check resources from the Triple Negative Breast Cancer Foundation.
It's worth asking your doctor about your specific tumor's genetic markers, as eligibility for many trials depends on factors like BRCA mutation status or PD-L1 expression.
June 1
Join
Your Privacy Choices
